Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05152459
Title Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma
Recruitment Not yet recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors City of Hope Medical Center

follicular lymphoma


Tazemetostat + Ublituximab + Umbralisib

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.